Topic
Topic
Pfizer's experimental atopic dermatitis candidate produced what the company called a "promising win" in a finance.yahoo.com syndicated headline, though specific molecule, trial phase, and efficacy en…
Medicus has named its melanoma antibody-drug conjugate a 'strategic priority' after closing a deal with Pfizer, concentrating res…
Pfizer has detailed Phase II data for its investigational atopic dermatitis candidate, setting up a direct mid-stage challenge to…
Pfizer's investigational IL-17 inhibitor tilrekimig produced a significant skin clearance signal in a Phase 2 atopic dermatitis t…
Tilrekimig, a first-in-class trispecific antibody targeting IL-4, IL-13 and TSLP, delivered EASI-75 rates up to 62.5% at Week 16…
Pfizer reports its trispecific antibody achieved significant skin clearance in a Phase 2 atopic dermatitis trial, signaling a pot…
Pfizer's eczema drug posted a 61% response rate the same day Florida sued the company, creating a split narrative of clinical pro…
Pfizer's experimental eczema drug achieved skin clearance in a mid-stage trial, advancing its atopic dermatitis candidate toward…
Pfizer has disclosed Phase 2 atopic dermatitis results for tilrekimig, its mid-stage candidate; detailed efficacy and safety data…
Pfizer says its eczema drug shows significant skin clearance in patients, a claim that puts the candidate in the competitive atop…
